$57.670
0.000 (0.00%)終値時点
ATRC のニュース
ATRC のイベント
BTIG Analyst Notes FDA Clearance for Edwards Lifesciences' ECLIPTIS System
BTIG analyst Marie Thibault notes that the FDA's 510(k) database reflected clearance of Edwards Lifesciences' (EW) ECLIPTIS left atrial appendage exclusion system, which the analyst says is positioned to compete directly with AtriCure's (ATRC) open AtriClip platform and Medtronic's (MDT) Penditure system. The firm, which anticipates "a measured, targeted rollout," adding that AtriClip has already demonstrated an ability to fend off a surgical valve incumbent, citing the company having held share against Medtronic's Penditure since its launch. The firm is not adjusting its estimates for Edwards or AtriCure at this time, the analyst tells investors.
Affirms FY26 Revenue View of $600M-$610M
Affirms FY26 revenue view of $600M-$610M, consensus $604.1M.
AtriCure Reports Q1 Revenue of $141.2M, Exceeding Expectations
Reports Q1 revenue $141.2M, consensus $139.8M. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined execution and increased adoption of our innovative products," said Michael Carrel, President and Chief Executive Officer at AtriCure. "Strong revenue growth, combined with improving profitability and meaningful advancement across our clinical initiatives, gives us confidence that we are building a foundation to drive the next era of growth and value creation for AtriCure and our shareholders."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。